<DOC>
	<DOC>NCT01069939</DOC>
	<brief_summary>To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from randomisation to occurrence of gastric and/or duodenal ulcers.</brief_summary>
	<brief_title>Comparative Efficacy &amp; Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin</brief_title>
	<detailed_description />
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Provision of written informed consent before starting the studyrelated procedures and examinations Patients who have the history of gastric and/or duodenal ulcer. A diagnosis of a chronic condition (angina pectoris, myocardial infarction and ischemic cerebrovascular disorder, etc., requiring prevention of thrombosis or embolism) which requires taking the prescribed LDA during the study treatment period. Having gastric or duodenal ulcer (except for ulcer scar). History of esophageal, gastric or duodenal surgery, except for simple closure of perforation.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Gastric ulcer</keyword>
	<keyword>Duodenal ulcer</keyword>
	<keyword>Low-dose aspirin</keyword>
</DOC>